
Last 4 earnings calls · through Q2 FY2026
Citing data center, semiconductor and space orders, the bull case holds that IDEX has moved its portfolio toward markets growing faster than industrial production.
Rising backlog and repeated guidance increases suggest the company can outgrow its industrial base without adding much capital or cost to serve the extra volume.
Cash flow pays for buybacks and dividends while the balance sheet stays modestly levered, so per-share results improve even if sales grow only moderately.
The bear case says HST's surge depends on capital spending by a handful of data center and chip customers, and order growth of this size rarely persists through a full cycle.
FMT and FSDP still supply a large share of revenue, and management describes their end markets as flat with only a few months of visibility into orders.
Profit flow-through on new HST volume has lagged IDEX's history, and part of recent margin came from a one-time tariff refund rather than from operations.
Life sciences, historically a profitable part of HST, remains held back by academic funding and Chinese demand, which weighs on the segment's mix and margins.
In short: HST orders and backlog are rising fast, while FMT and FSDP sales remain close to flat.
Management entered 2026 guiding to 1% to 2% organic growth and now expects 5% to 6%, citing HST's order book and a better start in FMT and FSDP.
Order growth in data center, semiconductor and space has lifted HST backlog for several quarters, giving visibility management rarely had in this business.
HST sales reached $415 million as data center, semiconductor and space work converted into shipments, making it the largest and fastest-growing segment.
FSDP sales fell 0.8% in the quarter, and dispensing and European fire markets remain weak, adding to the parts of IDEX that depend on an industrial recovery.
Management attributes just under half of the backlog increase to direct data center applications, tying a large share of new growth to one spending cycle.
In short: Cash generation is strong and margins are rising, while incremental profit on new volume has trailed history.
Buybacks and dividends totaled $515 million over the last year, about 80% of free cash flow, and the diluted share count has been shrinking.
After two quarters near 33% incremental margin, HST delivered high-30s flow-through excluding refunds as volume and richer mix came through.
Operating margin stayed at 21.7% even as revenue grew mid-single digits, showing that mix and acquired-business costs still absorb much of the added volume.
Management said the IEEPA refund added about 130 basis points to EBITDA margin, so reported profitability overstates the underlying second-quarter run rate.
In short: IDEX holds critical, low-cost positions in growing markets, while industrial and life science demand is slow.
IDEX sells critical components that are a tiny part of a customer's total system cost, which is why price increases have held even as customers pushed back.
A year ago management said it saw no inflection in its leading indicators; it now says signs of broad demand support are starting to form.
Revenue fell 10.7% in the 2008-2009 downturn but operating margin was unchanged and the company was back above its prior revenue peak the next year.
Core fluidics and optical filter sales grow only low single digits because US academic funding and demand from Chinese instrument makers remain weak.
European and Asian fire markets have not followed the North American recovery, and dispensing is shrinking as customers refurbish equipment instead of buying new.